No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 21
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for NeuroSense Therapeutics Ltd. (NRSN) stock was $4.07 as of Oct 6, 2026, 4:00 PM EDT, up 0.99% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.7% · 3-year avg -29.9%/yr
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions.
Biotechnology · Herzliya, TA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.06
vs Estimate
$-3.90
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NRSN | $7.19M | $4.07 | +0.99% | -83.74% | N/A | N/A | N/A |
| 2CODX | $7.19M | $1.15 | +4.55% | -90.34% | -66.53% | N/A | vs NRSN |
| 3LGVN | $7.15M | $2.35 | -6.37% | -67.97% | -62.60% | N/A | vs NRSN |
| 4SKYE | $7.12M | $1.62 | -6.36% | -95.38% | -60.42% | -46.85% | vs NRSN |
| 5INM | $7.31M | $1.33 | +0.00% | -41.77% | -71.98% | -52.81% | vs NRSN |
| 6KALA | $7.04M | $0.36 | +0.41% | -99.52% | -85.73% | N/A | vs NRSN |
forward FY estimate
N/A
vs Estimate
$535600.00
Consensus Rating
Based on 3 analysts
Average Price Target
$97.33
+2291.5% upside
Low
$52.00
Current
$4.07
High
$180.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Quarter ending Dec 2026 | $-3.17 | $-3.17 | $-3.17 | 1 |
| Quarter ending Mar 2027 | $-0.95 | $-0.95 | $-0.95 | 1 |
| Quarter ending Jun 2027 | $-4.70 | $-4.70 | $-4.70 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-8.00 | $-6.62 | $-4.45 | 2 |
| FY 2027 | $-14.37 | $-10.31 | $-6.24 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $535600.00 | $535600.00 | $535600.00 | 1 |
| Quarter ending Dec 2026 | $278500.00 | $278500.00 | $278500.00 | 1 |
| Quarter ending Mar 2027 | $1.57M | $1.57M | $1.57M | 1 |
| Quarter ending Jun 2027 | $1.64M | $1.64M | $1.64M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $714033.00 | $714067.00 | $714100.00 | 3 |
| FY 2027 | $2.61M | $3.28M | $3.95M | 2 |
